Skip to main content

Table 1 Summary of input values in the model

From: The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

Variable

Paediatric and AYA

74.4%

Reference

(27)

Variable

Adults 25.6%

Reference

(27)

Grouping (%)

HR

IR

SR

[18]

Grouping (%)

SR

HR

[3]

 

21.4

29.1

49.5

  

32.1

67.9

 

Age (years)

5

5

5

[18]

Age (years)

31

53

[1]

Body surface (m2)

0.75

0.75

0.75

RCPCH

Body surface (m2)

1.79

1.79

[33]

     

Eligible for transplant (%)

47

47

[34]

Health utilities decrements (%)

   

Assumption (decrement from [28])

Health utilities decrements (%)

  

Assumption (decrement from [28])

 Ind

25

25

25

 

 Ind

25

25

 

 C

16

16

16

 

 Int

25

25

 

 IM1

12

12

12

 

 C1

12

12

 

 DI1

12

12

12

 

 C3

12

12

 

 IM2

12

12

12

 

 M

7

7

 

 DI2

12

12

12

     

 CT

7

7

7

     

Hypersensitivity risk (%)

Hypersensitivity risk (%)

 Pegaspargase

 Pegaspargase

  first line (Ind)

2

2

2

[18]

  first line (Ind/Int)

2

2

Assumption

  second line (DI/C)

2

2

2

[18]

  second line (Int)

2

2

Assumption

 native asparaginase

 native asparaginase

  first line (Ind)

20

20

20

[29]

  first line (Ind)

20

20

Assumption

  second line (DI/C)

20

20

20

Assumption

  second line (Int)

20

20

Assumption

 Erwinia asparaginase

 Erwinia asparaginase

  second line (DI/C)

37

37

37

[30]

  second line (Int)

37

37

Assumption

 Impact

 Impact

  Utility decrement

0.014

0.014

0.014

[31]

  Utility decrement

0.014

0.014

[31]

  Cost (£)

470

470

470

[32]

  Cost (£)

470

470

[32]

5-year outcomes

5-year outcomes

 Asparaginase completed

 Asparaginase completed

  OS (%)

95

90

80

Assumption from [18]

  OS (%)

40

30

[3]

  EFS (%)

90

85

75

 

  EFS (%)

–

–

Assumption

 Asparaginase discontinued

 Asparaginase discontinued

  

EFS=OS

  RR for OS

0.95

0.95

0.95

Assumption

RR for OS

0.95

0.95

Assumption

  RR for EFS

0.95

0.95

0.95

Assumption

RR for EFS

–

–

Assumption

 

EFS=OS

Impact of R/STa

 Utility decrement (%)b

20

20

20

Assumption

    

 Increased mortality (%)c

90

90

90

Assumption

    
  1. C Consolidation, CT Continuation, DI Delayed intensification, EFS Event-free survival, HR High risk, IR Intermediate risk, IM Interim maintenance, Ind. Induction, Int. Intensification, M Maintenance, OS Overall survival, RCPCH Royal College of Paediatrics and Child Health, RR Relative risk, i.e. EFS (asparaginase discontinued) = RR EFS (asparaginase completed), R/ST Relapse/Secondary Tumour, SR Standard risk
  2. aPaediatric only. In Adults, EFS is assumed to equal OS
  3. bDecrement (%) from EQ-5D age-specific UK population norms.
  4. c2011–2013 data from England Life Tables [35].